|
Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT. |
|
|
Honoraria - Bayer; Exelixis; Onyx |
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Onyx; Oxigene |
Research Funding - Bayer (Inst); Eisai (Inst); Exelixis (Inst); Novartis (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Bayer; Eisai; Onyx |
|
|
Honoraria - AstraZeneca; Bayer; Eisai; Genzyme; SOBI |
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Genzyme |
Research Funding - AstraZeneca; Bayer; Eisai; Genzyme |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Merck Serono; Otsuka |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst) |
|
|
Consulting or Advisory Role - Ashion Analytics; AstraZeneca; Eisai |
|
|
Honoraria - AstraZeneca; Bayer; Eisai |
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai |
|
|
Honoraria - Bayer; Exelixis; Genzyme |
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Bayer; Exelixis; Genzyme |
Travel, Accommodations, Expenses - Genzyme |
|
|
Consulting or Advisory Role - AstraZeneca; Eisai; Genzyme |
Research Funding - AstraZeneca (Inst); Eisai (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Honoraria - Bristol-Myers Squibb; Merck Serono |
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); Ono Pharmaceutical (Inst) |
|
|
|
Travel, Accommodations, Expenses - Eisai |
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Exelixis; Onyx |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Eisai; Exelixis; Pfizer; Roche Pharma AG |
|
Other Relationship - Exelixis |
|
|
Consulting or Advisory Role - Eisai; Onyx; PDX Pharmacy |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Eisai (Inst); Merck KGaA (Inst); Novartis (Inst) |